Published in J Virol on July 01, 1981
Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells. J Virol (1985) 4.76
Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J Virol (1985) 3.76
Epstein-Barr virus RNA. VIII. Viral RNA in permissively infected B95-8 cells. J Virol (1982) 3.26
Mapping of polypeptides encoded by the Epstein-Barr virus genome in productive infection. Proc Natl Acad Sci U S A (1982) 2.20
Epstein-Barr virus glycoprotein homologous to herpes simplex virus gB. J Virol (1987) 1.87
Two major outer envelope glycoproteins of Epstein-Barr virus are encoded by the same gene. J Virol (1985) 1.82
An Epstein-Barr virus DNA fragment encodes messages for the two major envelope glycoproteins (gp350/300 and gp220/200). J Virol (1984) 1.76
Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo. J Virol (1982) 1.69
Identification of the Epstein-Barr virus gp85 gene. J Virol (1988) 1.61
Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes. J Virol (1988) 1.61
Induction of antibodies to the Epstein-Barr virus glycoprotein gp85 with a synthetic peptide corresponding to a sequence in the BXLF2 open reading frame. J Virol (1988) 1.42
Synthesis and processing of the three major envelope glycoproteins of Epstein-Barr virus. J Virol (1983) 1.41
Posttranslational processing of the Epstein-Barr virus-encoded p63/LMP protein. J Virol (1987) 1.33
Infection of B lymphocytes by a human herpesvirus, Epstein-Barr virus, is blocked by calmodulin antagonists. Proc Natl Acad Sci U S A (1984) 1.31
Strain-specific transcription and translation of the BamHI Z area of Epstein-Barr Virus. J Virol (1986) 1.31
Two large virion envelope glycoproteins mediate Epstein-Barr virus binding to receptor-positive cells. J Virol (1982) 1.21
Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes. Proc Natl Acad Sci U S A (1982) 1.16
Immunobiochemical characterization with monoclonal antibodies of Epstein-Barr virus-associated early antigens in chemically induced cells. J Virol (1984) 1.13
Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells. J Virol (1987) 1.13
Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor. Cell Rep (2013) 0.99
The B95-8 isolate of Epstein-Barr virus arose from an isolate with a standard genome. J Virol (1982) 0.96
Inhibition of Epstein-Barr virus (EBV) release from P3HR-1 and B95-8 cell lines by monoclonal antibodies to EBV membrane antigen gp350/220. J Virol (1988) 0.87
EBV Persistence-Introducing the Virus. Curr Top Microbiol Immunol (2015) 0.82
Inhibition of Epstein-Barr virus (EBV) release from the P3HR-1 Burkitt's lymphoma cell line by a monoclonal antibody against a 200,000 dalton EBV membrane antigen. J Exp Med (1985) 0.80
Interaction of human tumor viruses with host cell surface receptors and cell entry. Viruses (2015) 0.78
Mapping of B-cell epitopes on the polypeptide chain of the Epstein-Barr virus major envelope glycoprotein and candidate vaccine molecule gp340. J Virol (1992) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels. Eur J Biochem (1974) 113.22
Rapid isolation of antigens from cells with a staphylococcal protein A-antibody adsorbent: parameters of the interaction of antibody-antigen complexes with protein A. J Immunol (1975) 47.77
Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol (1966) 18.33
Persisting oncogenic herpesvirus induced by the tumour promotor TPA. Nature (1978) 9.25
Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis. Proc Natl Acad Sci U S A (1968) 8.67
Differential reactivity of human serums with early antigens induced by Epstein-Barr virus. Science (1970) 7.60
MORPHOLOGICAL AND BIOLOGICAL STUDIES ON A VIRUS IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. J Exp Med (1965) 4.76
Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology (1979) 4.02
Proteins of Epstein-Barr virus. I. Analysis of the polypeptides of purified enveloped Epstein-Barr virus. J Virol (1976) 3.83
Search for tumor-specific immune reactions in Burkitt lymphoma patients by the membrane immunofluorescence reaction. Proc Natl Acad Sci U S A (1966) 3.56
Precipitating antibody in human serum to an antigen present in cultured burkitt's lymphoma cells. Proc Natl Acad Sci U S A (1966) 3.56
DNA of Epstein-Barr virus. IV. Linkage map of restriction enzyme fragments of the B95-8 and W91 strains of Epstein-Barr Virus. J Virol (1978) 3.41
Malignant lymphoma in cottontop marmosets after inoculation with Epstein-Barr virus. Proc Natl Acad Sci U S A (1973) 3.14
Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. J Natl Cancer Inst (1969) 3.07
Suppression of in vitro Epstein-Barr virus infection. A new role for adult human T lymphocytes. J Exp Med (1977) 2.65
Tunicamycin--an inhibitor of yeast glycoprotein synthesis. Biochem Biophys Res Commun (1974) 2.64
Tumor initiators and promoters in the induction of Epstein-Barr virus. Proc Natl Acad Sci U S A (1979) 2.55
Suppression of glycoprotein formation of Semliki Forest, influenza, and avian sarcoma virus by tunicamycin. J Virol (1976) 2.51
Activation of latent Epstein-Barr virus by antibody to human IgM. Nature (1978) 2.33
Immunochemical characterization of Epstein-Barr virus-associated early and late antigens in n-butyrate-treated P3HR-1 cells. J Virol (1979) 2.31
Epstein-Barr virus-induced membrane antigens: immunochemical characterization of Triton X-100 solubilized viral membrane antigens from EBV-superinfected Raji cells. Int J Cancer (1979) 1.89
Polypeptides of the Epstein-Barr virus membrane antigen complex. J Virol (1979) 1.86
A new tumour-derived transforming strain of Epstein-Barr virus. Nature (1978) 1.84
Preparation and properties of lymphocyte plasma membrane. Contemp Top Mol Immunol (1974) 1.75
Correlation between Epstein-Barr virus membrane antigen and three large cell surface glycoproteins. J Virol (1979) 1.71
Epstein-Barr virus-associated antibody patterns in carcinoma of the post-nasal space. Clin Exp Immunol (1969) 1.68
Appearance of Epstein-Barr virus-associated antigens in infected Raji cells. Virology (1971) 1.68
Biological and biochemical observations on isolates of EB virus from the malignant epithelial cells of two nasopharyngeal carcinomas. Int J Cancer (1979) 1.62
Relationship between the EBV-associated membrane antigen on Burkitt lymphoma cells and the viral envelope, demonstrated by immunoferritin labelling. Int J Cancer (1971) 1.50
Characterization of cross-reacting antigens on the Epstein-Barr virus envelope and plasma membranes of producer cells. Cell (1979) 1.48
Mechanisms of infection with Epstein-Barr virus. I. Viral DNA replication and formation of noninfectious virus particles in superinfected Raji cells. J Virol (1976) 1.41
Epstein-Barr virus-induced proteins. II. Analysis of surface polypeptides from EBV-producing and -superinfected cells by immunoprecipitation. Virology (1980) 1.34
Differentiation between early and late membrane antigen on human lymphoblastoid cell lines infected with Epstein-Barr virus. I. Immunofluorescence. J Natl Cancer Inst (1974) 1.18
A virus-free immunogen effective against Epstein-Barr virus. Nature (1979) 1.06
Enhancement of Epstein-Barr virus replication in producer cell lines by a combination of low temperature and corticosteroids. Virology (1979) 0.95
An immunoferritin study of a Burkitt lymphoma cell line harboring EB virus particles. Gan (1970) 0.85
Ultraviolet inactivation of Epstein-Barr virus: effect on synthesis of virus-associated antigens. Int J Cancer (1975) 0.81
Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells. J Virol (1985) 4.76
EBV persistence in memory B cells in vivo. Immunity (1998) 4.44
Early events in Epstein-Barr virus infection provide a model for B cell activation. J Exp Med (1985) 3.19
A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell (1995) 3.17
The Kaposi sarcoma-associated herpesvirus (KSHV) is present as an intact latent genome in KS tissue but replicates in the peripheral blood mononuclear cells of KS patients. J Exp Med (1996) 2.67
BLAST-2 [EBVCS], an early cell surface marker of human B cell activation, is superinduced by Epstein Barr virus. J Immunol (1985) 2.66
Suppression of in vitro Epstein-Barr virus infection. A new role for adult human T lymphocytes. J Exp Med (1977) 2.65
Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity. Proc Natl Acad Sci U S A (1980) 2.59
Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J Virol (1997) 2.53
Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med (1999) 2.27
The activation antigen BLAST-2, when shed, is an autocrine BCGF for normal and transformed B cells. EMBO J (1987) 2.16
B cell activation and the establishment of Epstein-Barr virus latency. J Exp Med (1988) 2.00
Epstein-Barr virus superinduces a new human B cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts. Cell (1982) 1.95
Is EBV persistence in vivo a model for B cell homeostasis? Immunity (1996) 1.94
All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts. J Virol (1993) 1.92
Detection of the latent form of Epstein-Barr virus DNA in the peripheral blood of healthy individuals. J Virol (1996) 1.92
Polypeptides of the Epstein-Barr virus membrane antigen complex. J Virol (1979) 1.86
Epstein-Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity (2001) 1.75
When Epstein-Barr virus persistently infects B-cell lines, it frequently integrates. J Virol (1991) 1.70
Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo. J Virol (1982) 1.69
New common nomenclature for glycoprotein genes of varicella-zoster virus and their glycosylated products. J Virol (1986) 1.59
Cross-reactivity between herpes simplex virus glycoprotein B and a 63,000-dalton varicella-zoster virus envelope glycoprotein. J Virol (1985) 1.56
Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proc Natl Acad Sci U S A (2000) 1.56
Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. J Virol (2000) 1.55
Localization of the major NF-kappaB-activating site and the sole TRAF3 binding site of LMP-1 defines two distinct signaling motifs. J Biol Chem (1997) 1.51
EBV persistence involves strict selection of latently infected B cells. J Immunol (2000) 1.50
An unusually high-titer human anti-Epstein Barr virus (EBV) serum and its use in the study of EBV-specific proteins synthesized in vitro and in vivo. J Immunol (1983) 1.49
Characterization of cross-reacting antigens on the Epstein-Barr virus envelope and plasma membranes of producer cells. Cell (1979) 1.48
Synthesis and processing of the three major envelope glycoproteins of Epstein-Barr virus. J Virol (1983) 1.41
The prototypical Epstein-Barr virus-transformed lymphoblastoid cell line IB4 is an unusual variant containing integrated but no episomal viral DNA. J Virol (1991) 1.31
Identification of the products of a varicella-zoster virus glycoprotein gene. J Gen Virol (1985) 1.31
Expression of the Blast-1 activation/adhesion molecule and its identification as CD48. J Immunol (1991) 1.30
Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein. Proc Natl Acad Sci U S A (1987) 1.28
Studies on the location and orientation of proteins in the sarcoplasmic reticulum. Eur J Biochem (1973) 1.27
Differential effect of phosphonoacetic acid on the expression of Epstein-Barr viral antigens and virus production. Proc Natl Acad Sci U S A (1976) 1.22
Attachment of Giardia lamblia to rat intestinal epithelial cells. Gut (1988) 1.18
The suppression of Epstein-Barr virus infection in vitro occurs after infection but before transformation of the cell. J Immunol (1980) 1.17
An Epstein-Barr virus-associated superantigen. J Exp Med (1996) 1.17
Biochemical analysis suggests distinct functional roles for the BLAST-1 and BLAST-2 antigens. J Immunol (1986) 1.15
Varicella-zoster virus envelope glycoproteins: biochemical characterization and identification in clinical material. Virology (1985) 1.14
Blast-1 possesses a glycosyl-phosphatidylinositol (GPI) membrane anchor, is related to LFA-3 and OX-45, and maps to chromosome 1q21-23. J Exp Med (1989) 1.11
Processing of the Epstein-Barr virus-encoded latent membrane protein p63/LMP. J Virol (1990) 1.07
The reactivity of the thiol groups of the adenosine triphosphatase of sarcoplasmic reticulum and their location on tryptic fragments of the molecule. Biochem J (1977) 1.06
A virus-free immunogen effective against Epstein-Barr virus. Nature (1979) 1.06
Analysis of cellular immune response to EBV by using cloned T cell lines. J Immunol (1983) 1.05
Changes in glucosamine and galactosamine levels during conidial germination in Neurospora crassa. J Bacteriol (1975) 1.05
Reversible inhibition by phosphonoacetic acid of human B lymphocyte transformation by Epstein-Barr virus. Virology (1978) 1.00
Biochemical, genetic, and functional analyses of the phosphorylation sites on the Epstein-Barr virus-encoded oncogenic latent membrane protein LMP-1. J Virol (1993) 0.99
Molecular cloning of the lymphocyte activation marker Blast-1. EMBO J (1987) 0.99
A virtual look at Epstein-Barr virus infection: simulation mechanism. J Theor Biol (2008) 0.97
Epstein-Barr virus antigens-a challenge to modern biochemistry. Adv Cancer Res (1982) 0.97
Separation and characterisation of tryptic fragments from the adenosine triphosphatase of sarcoplasmic reticulum. Eur J Biochem (1975) 0.97
Purification and properties of poly(adenosine diphosphate ribose) synthetase. J Biol Chem (1977) 0.96
Surface antigen changes during B-lymphocyte activation in primates. Cell Immunol (1984) 0.95
An 88,000-Mr Giardia lamblia surface protein which is immunogenic in humans. Infect Immun (1986) 0.94
Schistosoma mansoni: genetic restriction and cytokine profile of the CD4 + T helper cell response to dominant epitope peptide of major egg antigen Sm-p40. Exp Parasitol (1998) 0.90
Characterization of the CD48 gene demonstrates a positive element that is specific to Epstein-Barr virus-immortalized B-cell lines and contains an essential NF-kappa B site. J Virol (1995) 0.88
CD48 binds to heparan sulfate on the surface of epithelial cells. J Biol Chem (1998) 0.88
A ligand for human CD48 on epithelial cells. J Immunol (1997) 0.86
Detection of EBV infection at the single-cell level. Precise quantitation of virus-infected cells in vivo. Methods Mol Biol (2001) 0.84
Biochemical and genetic studies on galactosamine metabolism in Neurospora crassa. J Bacteriol (1976) 0.84
A new form of Epstein-Barr virus latency in vivo. Curr Top Microbiol Immunol (1995) 0.82
Genomic integration as a novel mechanism of EBV persistence. Curr Top Microbiol Immunol (1990) 0.82
A rapid procedure for the enrichment of undenaturated, antigenically active herpes simplex virus glycoproteins. J Virol Methods (1984) 0.80
Ia.W39 expression correlates with a specific Ir function. J Immunol (1982) 0.80
Detection and discrimination of latent and replicative herpesvirus infection at the single cell level in vivo. Methods Mol Biol (2001) 0.78
Is there a unique episome in EBV transformed B cells? Virology (1991) 0.78
Characterization of the Epstein-Barr virus-inducible gene encoding the human leukocyte adhesion and activation antigen BLAST-1 (CD48). Mol Cell Biol (1991) 0.78
Mutational analysis of the transforming function of the EBV encoded LMP-1. Curr Top Microbiol Immunol (1992) 0.76
Characterization of genomic polymorphism of an activation-associated antigen, Blast-1. Immunogenetics (1990) 0.76
Reaction of 1-fluoro-2,4-dinitrobenzene and 2,4,6-trinitrobenzenesulphonic acid with membranes of sarcoplasmic reticulum. Biochem J (1980) 0.75
The interplay of herpesviruses in AIDS: superantigen sharing. Trends Microbiol (1996) 0.75
Preliminary studies on the structure of the calcium-activated adenosine triphosphatase of sarcoplasmic reticulum. Biochem Soc Symp (1974) 0.75
Suppression of in vitro Epstein-Barr virus infection: a new role for adult human T-lymphocytes. IARC Sci Publ (1978) 0.75